China’s Tasly Mixes Western Drug-Making Art With Herbal Work
This article was originally published in PharmAsia News
China's Tianjin Tasly Pharmaceutical relies on the accepted methods of manufacturing chemical-based pharmaceuticals for use in the herbal medicine market. Tasly's Fufang Danshen Diwan pill for emergency coronary treatment was the first herbal treatment cleared by the U.S. FDA for clinical trials and accounted for $80 million of the firm's sales last year. The firm's leaders attribute the success to the firm's use of production and presentation methods, research into a medicine's molecular formula and other R&D work to make its wares more acceptable in the U.S. and European markets. (Click here for more
You may also be interested in...
Chugai is pursuing further Japanese litigation over generic rivals to its Edirol brand, this time concerning the eldecalcitol ingredient produced by Nissan Chemical.
The European Commission has unexpectedly concluded that CBD should not be considered as a drug opening up the path to a regulated EU market for the cannabinoid as a novel food.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.